These results confirmed the independence of both biomarkers from the classical categorization of breast carcinomas and from the five breast cancer subtypes, and reinforce their intrinsic value as biomarkers for predicting BrM relapse, whereas TRAF2 and Inhibin were no longer significant (p = 0.481 and p = 0.736, respectively). The gene discussed is TRAF2; the disease is breast carcinoma.